Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer

Fig. 4

NPpCXCL9/10/11 exhibits an efficient antitumor effect in the subcutaneous LLC tumor model. A Tumor growth curve. Subcutaneous LLC tumor model was established in C57BL/6 mice, and mice were intravenously treated with FreepCXCL9/10/11 or NPpCXCL9/10/11 every 3 days for 6 repeats when the tumor volumes reached about 50 mm3, the equivalent injection dose of pCXCL9, pCXCL10, and pCXCL11 was 15 μg per mice. The levels of CXCL9, CXCL10, and CXCL11 in the tumor tissues were examined by western blot (B) and ELISA (C) at the end of the anti-tumor study. D Tumor tissues were digested and the ratios of CD4 + and CD8 + T cells in the CD45 + tumor-infiltrating immune cells were examined by multi-color flow cytometry. A representative flow cytometry image was shown. The percentages of CD4 + T cells (E) and CD8 + T cells (F) in CD45 + cells were calculated. G Distributions of T cells were evaluated by (2) of CD3. ELISA results of cytokines production in the tumors from mice receiving indicated treatments (H: TGF-β; I: IL12p70; J: IFN-γ). Data represent means ± SD. n = 6 mice, **p < 0.01, ***p < 0.001

Back to article page